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Abstract
Background—The diagnosis of ectopic pregnancy in women presenting in early pregnancy is
often protracted, relying on costly investigations that are psychologically burdensome to the
patient. The aim of this study was to evaluate the financial costs to the health services in Scotland
of the current methods used to diagnose and exclude ectopic pregnancy, and compare these with
that of a theoretical single diagnostic serum biomarker.
Methods—We conducted a retrospective cost description analysis (with and without costs of
diagnostic laparoscopy) of the healthcare costs incurred by all patients presenting to a large
Scottish teaching hospital between June and September 2006 with pain and bleeding in early
pregnancy, where ectopic pregnancy was not excluded. Additionally, a cost minimisation analysis
was performed of the costs of current ectopic pregnancy investigations versus those of a
theoretical single diagnostic serum biomarker. This included sensitivity analyses where the
biomarker was priced at increasing values and assumed to have less than 100% diagnostic
sensitivity and specificity.
Results—175 patients were eligible to be included in the analysis. 47% of patients required more
than 3 visits to diagnose or exclude ectopic pregnancy. The total yearly cost for diagnosing and
excluding ectopic pregnancy was £197K for the hospital stated, and was estimated to be £1,364K
for Scotland overall. Using a theoretical diagnostic serum biomarker we calculated that we could
save health services up to £976K (lowest saving £251K after subanalyses) every year in Scotland.
Conclusions—Ectopic pregnancy is expensive to diagnose and exclude, and the investigation
process is often long and might involve significant psychological morbidity. The development of a
single diagnostic serum biomarker would minimise this morbidity and lead to significant savings
of up to £1 million pounds per year in Scotland.
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Introduction
Ectopic pregnancy is a considerable cause of morbidity and mortality (Farquhar, 2005;
Walker, 2007). UK data from the confidential enquiry into maternal deaths demonstrates a
static number of deaths from ectopic pregnancy over the past twenty years (Saving Mother’s
Lives, 2008), with the rate of ectopic pregnancy remaining unchanged at around 1.5% of
pregnancies, or even slightly increasing (Seror, 2007).
Despite medical advances, the diagnosis of ectopic pregnancy in women presenting in early
pregnancy remains difficult. The majority present with pain and bleeding, common
symptoms which can also be incidental, or due to miscarriage (one in five pregnancies).
Currently we rely on a combination of serial serum beta-human chorionic gonadotrophin
(hCG) levels and ultrasound to differentiate ectopic from intrauterine gestation. These tests
are time-consuming and costly for the health services and likely to be psychologically
burdensome to the patient. Despite advances in scanning in practice, less than 50% of
ectopic pregnancies are diagnosed at the initial visit, and laparoscopy is occasionally needed
to confirm the diagnosis, a procedure that involves risk to the patient and considerable
expense for the health services (Robson and O’Shea, 1996; Munro et al, 2008).
Consequently, over 20 serum biomarkers have been identified to date in an attempt to permit
earlier diagnosis of ectopic pregnancy, the instigation of earlier management and reduce
healthcare costs (reviewed in Cartwright et al., 2009). Disappointingly, the clinical utility of
these biomarkers has been limited because of variable results due, for the most part, to
limitations in study design. In many studies, the cohort that was examined was very small
and the prevalence of ectopic pregnancy within the study population was not constant. In
some studies, patients were not accurately matched for gestation (in part due to the general
nature of an ectopic pregnancy, which is typically difficult to age). Some of the serum
biomarkers also limited their own use, as they did not follow a steady pattern (increase or
decrease) with normal a normal gestation. Furthermore, changes in the serum assays and the
reagents used to detect the biomarkers over the decades have also led to differing results
between the studies. We are therefore undertaking a biomarker discovery programme, using
carefully selected cohorts of women and microarray technology in Edinburgh, in an attempt
to overcome previous limitations in study design with a view to facilitating the rapid and
accurate diagnosis of tubal ectopic pregnancy (Horne et al, 2008; Horne et al, 2009).
Recently there has been increased emphasis on resource allocation approaches to maximise
the health of the population given the limited resources available. Optimum or ‘well-
informed’ decisions regarding resource allocation requires the costs and benefits of
alternative strategies to be considered within a systematic framework (McIntosh and
Luengo-Fernandez, 2006; Cochrane, 1972). The National Institute of Clinical Excellence
(NICE) in the UK recommends that economic evaluations address the costs incurred (or
saved) by its National Health Service (NHS) (NICE, 2004).
The aim of this study was to: (i) perform a cost-description analysis of the current methods
used to diagnose or exclude ectopic pregnancy, and (ii) to use a cost-minimisation analysis
approach to compare current costs against estimated costs for a theoretical single diagnostic
serum biomarker.
Materials and methods
Study population and data collected
A retrospective analysis was conducted of all women with symptoms of pain and bleeding in
early pregnancy presenting to the Pregnancy Support Centre at the Royal Infirmary of
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Edinburgh (RIE) (a large Scottish teaching hospital) between 1st June 2006 and 30th
September 2006. Management was protocol-based, reflecting experience of managing a
large population of women in early pregnancy and current practice. On admission all
patients had an ultrasound scan and/or serum human chorionic gonadotropin (hCG) level. If
the scan showed either an empty uterus, or small intrauterine sac but no fetal pole or yolk
sac was identified, and/or hCG levels were inconclusive, then the woman was either
classified as ‘suspected ectopic pregnancy’ (diagnostic) or ‘ectopic not excluded’ (non-
diagnostic). The study comprised all women classified in these categories. Comprehensive
care pathway data were collected for each woman in the study group. This information
included any further hospital visits, ultrasound scans (transabdominal and transvaginal),
serum hCG blood tests, endometrial biopsies, doctor consultations and laparoscopies
performed. Doctor consultations were only included where the primary aim was diagnosis
and not management. Similarly, laparoscopy was only included if the primary aim as an
investigation was of diagnosis (albeit in some cases the laparoscopy was used for
management as well).
Cost-description analysis
The costs were assessed from the point of view of the NHS in the UK. This incorporated
only the costs directly attributable to the NHS, including staffing (nurses’ and doctors’
time), investigations (measurement of serum hCG levels, ultrasound scans, endometrial
biopsies and laparoscopies), consumables and overhead costs (Drummond et al, 2005). Unit
costs were defined using ISD Scotland prices (www.isdscotland.org) for April 2006 – March
2007, specific to the RIE, Edinburgh, taking the figures for net cost per attendance (see
Table I). Costs that were not specified by ISD Scotland (endometrial biopsy and diagnostic
laparoscopy) were obtained from a previously published economic study undertaken at the
RIE (Critchley et al, 2004), a strategy recommended by Drummond et al, 2005. The direct
financial costs of the investigations these patients underwent were calculated by multiplying
the quantities of resources used by the unit costs of the resources (Johnson et al, 1999). The
total cost for patients at the first visit was calculated and a mean cost per patient for that visit
was determined. The same calculation was undertaken for all patients attending for second,
and subsequent, visits. A cumulative cost for each additional visit was calculated as the sum
of costs from each visit of the diagnostic pathway, and a mean cost per patient per number
of visits required was found. All costs were expressed in Pounds Sterling (£) and rounded up
to the nearest £. Where the costs are in thousands, the letter ‘K’ denotes thousand. The total
cost for all of the visits’ investigations for the four months was extrapolated to estimate the
cost of diagnosing or excluding ectopic pregnancy over one full year. Data from ISD
Scotland on the rates of ectopic pregnancy recorded 747 ectopic pregnancies in Scotland
during 2006 (Scottish Morbidity Record databases, SMR01 and SMR02, for 2006, ISD
Scotland). Using this data a ratio was calculated for the estimated annual rate of ectopic
pregnancies at the RIE relative to that of Scotland. This was then used to extrapolate our
figures further to the whole of Scotland to provide an estimate of the financial cost of
investigations for ectopic pregnancies nationwide for 2006.
Cost-comparison analysis: current investigations versus a theoretical single diagnostic
serum biomarker
A cost comparison was performed between the current ectopic pregnancy investigations
versus those of a theoretical single diagnostic serum biomarker (Horne et al, 2008; Horne et
al, 2009; Cartwright et al, 2009) costed at the same price as a routine hCG (£0.43). In this
scenario each patient was taken as having one nurse-led clinic visit with an ultrasound scan
and a single blood test. The cost comparison was performed as a cost-minimisation analysis
as the outcomes of both diagnostic pathways are the same.
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Sensitivity analyses
A sensitivity analysis examining pricing the biomarker at increasing values from £0.43
(current cost of serum hCG test) to £200 was conducted, and the cost difference was
calculated compared to the cost at present. Additional sensitivity analyses, based on the
assumption that the biomarker will have a sensitivity and specificity of less than 100%, were
also conducted by recalculating the costs using the assumption that varying proportions (say
10, 20 and 40%) of women will need more than one visit (for example, when the biomarker
results might still be equivocal).
Results
1162 patients presented to the RIE between 1st June 2006 and 30th September 2006 with
symptoms of pain or bleeding in early pregnancy. Following an ultrasound scan, or in some
cases hCG serum level (if they presented too early for a scan or they presented out of hours
when the ultrasound service was not available), 180 patients were categorised as ‘diagnostic’
or ‘non-diagnostic.’ Five of these patients completed their diagnostic pathway after the
specified timeframe and were therefore excluded from the total costs. Of the 175 patients
included in the cost description analysis, six were managed as an ectopic pregnancy at their
first visit, nine were lost to follow-up, and 160 went on to have further investigations. Of the
nine lost-to-follow-up, there were four who moved away and attended a hospital elsewhere,
four who did not return anywhere for a second appointment, and one who was monitored by
hCGs by her GP.
Figure 1 shows the diagnostic pathway for the 175 patients. All pathways began with
presentation to hospital. During each visit a certain number of ectopic pregnancies were
identified and treated, and a certain number of pregnancies were confirmed as either viable,
miscarriage, or given another diagnosis. Those patients with confirmed diagnoses were then
removed from the diagnostic pathway. Figure 2 shows the cumulative number of patients
who were diagnosed ‘ectopic’ or ‘discharged’, and the number continuing ‘non-diagnostic’
across successive hospital visits. In total, 36 ectopic pregnancies were identified over the
four months.
The investigations needed by the 175 patients up until they were given a diagnosis are
presented in Table II. Total costs of the investigations used were calculated depending on
the number of visits needed. The mean cost per patient who has one visit and the cumulative
costs for subsequent visits were then calculated (Table II). As expected, costs per patient
increased with number of visits. Laparoscopy was particularly expensive but was only
included in costs if used as a diagnostic tool. In all but one case, patients undergoing
laparoscopy were confirmed to have ectopic pregnancy.
Based on these figures, we estimated that the total yearly cost for diagnosing and excluding
ectopic pregnancy at the RIE to be £197K. Using further epidemiological data from ISD
Scotland, we extrapolated this value to the whole of Scotland and estimated the total yearly
cost for diagnosing and excluding ectopic pregnancy in Scotland to be £1,364K.
The cost comparison revealed that using a theoretical diagnostic serum biomarker the total
yearly cost for diagnosing and excluding ectopic pregnancy in Scotland would be £387K
and therefore such a test could save the NHS £976K over the year in Scotland (at 2006
costs).
We acknowledge that all samples are subject to sampling error and chained error potential.
The figure for ectopic pregnancy (36/175) has a 95% confidence interval (CI) for events
(ectopic pregnancy diagnoses) of 24 to 48 in four months and 72 to 144 per year.
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Conducting the cost description using these figures gives the range of possible cost estimates
of diagnosing and excluding ectopic pregnancy to be: £1,023K to £2,045K per year in
Scotland (Kirkwood and Sterne, 2003).
In addition, we conducted a sub-analysis including the five women who had been excluded
as their pathway finished outside of the timeframe. In this scenario the total yearly cost for
diagnosing and excluding ectopic pregnancy in Scotland was £1,354K. In this case the NHS
saving by using the theoretic diagnostic serum biomarker is estimated at £977K.
The surprisingly high diagnostic rate of laparoscopies suggested that the presumption of use
for diagnosis was not as high as ascertained from the notes. We therefore also conducted a
separate cost description analysis without including the laparoscopy costs on the basis of
assuming that laparoscopies were not entirely diagnostic and more likely to be therapeutic
(Table III). This made the total yearly cost for diagnosing and excluding ectopic pregnancy
in Scotland £1,085K. In this case, the NHS saving by using the theoretic diagnostic serum
biomarker is estimated at £698K.
A sensitivity analysis was performed comparing the money saved in Scotland per year by
costing the serum biomarker at £0.43, £10, £100, £150 and £200 (Table IV). These costs
would allow for the serum biomarker to be analysed using more expensive techniques
including polymerase chain reaction, for example. In addition, a separate sensitivity analysis
was conducted to investigate the money saved in Scotland per year by using a serum
biomarker that was not 100% sensitive. This was performed by assuming 10, 20 and 40% of
women needed 2 or 3 visits to make a diagnosis (see Table V).
Discussion
This study offers novel information on the economic cost of investigating ectopic pregnancy
which as far as we are aware has not been calculated previously. It provides a descriptive
account of the costs to NHS Scotland of diagnosing and excluding ectopic pregnancy under
the current care pathway approach to management, showing that ectopic pregnancy is
expensive to diagnose and exclude, and the investigation process may be long and thus
involve significant psychological morbidity. In addition, it demonstrates that the
development of a single diagnostic serum biomarker test to diagnose/exclude ectopic
pregnancy at presentation would minimise this morbidity and save the NHS around £1
million per year in Scotland. This has important implications for the improvement of
diagnosing ectopic pregnancy and patient well-being in an economic environment where
resources are limited.
Overall we showed that nearly half the patients (47%) required at least three visits in order
to diagnose or exclude ectopic pregnancy. As expected, laparoscopy raised the mean cost the
most, however, cost of diagnosis predictably increased with visit number. Therefore,
development of a single serum biomarker which would require one visit to diagnose ectopic
pregnancy would be substantially advantageous financially, particularly if it cost £10 or less
(see sensitivity analysis). However, sensitivity analyses also show that even if the biomarker
was more expensive (for example, to cover laboratory costs and individual technician
supervision), or not 100% sensitive, and a proportion of women required further visits, the
results continue to demonstrate a significant saving to the NHS.
We have tried to eliminate bias as far as possible from our estimates for the RIE, and for
Scotland, however, the extrapolated figures represent estimates. By calculating the
confidence intervals and conducting the subanalysis, including the costs of the pathways for
the five women who completed their pathway after the time window had elapsed, we
demonstrate that the total costs do not change significantly. The subanalysis of the results
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also demonstrates that the total cost remains high even when the costs of the diagnostic
laparoscopies are not included (allowing for the fact that they were not solely used for
diagnostic purposes). It is however likely that the pattern of care at a tertiary centre, such as
the RIE, is different to that in a more rural location (i.e. laparoscopies are used more often
for diagnostic purposes) and that inclusion of laparoscopic costs is pertinent. We have not
included bed-night costs as we were only looking at diagnostic costs. However, as PSC care
is not 24 hour, some patients are admitted and stay in the ward over night. In rural areas,
more patients may be admitted overnight and further increase the cost.
Several positive methodological aspects of this study merit discussion. One of its strengths
is that it is a thorough retrospective analysis of all of the patients that presented during the
specified time period (the dataset was completed with no missing values). A second strength
was that it used a national hospital-cost database to provide estimates of costs representative
of the situation throughout the UK (www.isdscotland.org) (Seror et al, 2007) A further
strength was that the method used in the economic evaluation (a cost-minimisation analysis
of the present investigation route and that of a theoretical new biomarker) is part of a cost-
effectiveness analysis and represents a full economic evaluation (the optimum comparative
analysis of alternative courses of action) (Drummond et al, 2005). The majority of cost-
effectiveness analyses have been conducted on treatment/intervention strategies where
outcome may be measured. However, in an analysis of investigations, such as that
performed in this study, it is harder to define a suitable effect (the outcome of diagnosing an
ectopic pregnancy is intrinsically dependent on the investigation).
Nonetheless, our study has limitations as it was not population-based and therefore
extrapolation to nationwide areas is only an estimate. Despite this drawback, the method
used for extrapolation was based on a ratio of the number of ectopics diagnosed at the RIE
compared to Scotland where a value was obtained from the SMR system. It has been found
that the rate of ectopic pregnancy recorded in the SMR system underestimates, as it only
include inpatients and more patients are cared for on an outpatient basis. This suggests that
the study actually underestimates the cost of diagnosing and excluding ectopic pregnancy in
Scotland. We also acknowledge that endometrial biopsy and laparoscopy costs were taken
from a different source and discounting has not been applied, however, the likelihood is this
would only increase the cost further. Furthermore, the diagnostic pathway in this evaluation
is used by the main teaching hospital in Edinburgh. Early pregnancy units throughout
Scotland will use slightly different diagnostic pathways. Nevertheless, the pathways are all
based on nationally agreed evidence-based guidelines (RCOG 2004) and so it is unlikely
that they differ extensively.
Another limitation is that the serum biomarker is only in the developmental stage and the
cost was approximated to that of clinical chemistry at present. However, sensitivity analyses
of increasing biomarker costs indicated that a significant financial benefit could still
obtained. Additionally, the biomarker was given 100% sensitivity and specificity which may
not be realistic. However, given the substantial savings indicated, a financial benefit may
still be inferred even with considerably lower sensitivity and specificity.
The investigative procedures may have further important financial consequences for the
patient or caregiver, for example in travel and time costs, which will not be taken into
account using this narrower perspective of only direct healthcare costs. Wider perspectives
take account of direct costs (medical and non medical) and indirect costs (productivity costs
due to mortality and morbidity). These include other direct costs such as those of related
services (ambulance services), the costs to the patient and family to come to the hospital and
drugs that are purchased over the counter (for example, for pain following an uncomfortable
procedure). The indirect costs include the costs to patient/family through time lost from
Wedderburn et al. Page 6
Hum Reprod. Author manuscript; available in PMC 2010 November 23.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
work (opportunity costs) and those additional costs of being in hospital such as
childminding. Women affected by ectopic pregnancy are at the stage in life where they are
most affected by this as they are likely to work, or have a family, or both, making these
indirect costs extremely significant.
Furthermore, it is likely that multiple hospital visits and tests also have a psychological
impact on patient wellbeing. Therefore, the development of a new diagnostic biomarker has
the potential not only to save money for healthcare services but also save have benefits both
financially and psychologically for patients and families.
In summary, ectopic pregnancy is expensive to diagnose and a serum biomarker would be a
cost-effective alternative by maximising the health outcomes within limited health services’
budgets, and therefore maximising the welfare of society within resources available (Byford
and Raftery, 1998). More research is required to develop such a test, or multiple tests, or
other imaging modalities to improve the diagnosis of ectopic pregnancy.
Acknowledgments
The authors would like to thank Ronnie Grant for his invaluable assistance with the design of all figures and tables,
and the staff of the Pregnancy Support Centre (RIE) for their helpful input.
Funding
The authors received no sponsorship for the project.
References
Bateman, IJ.; Carson, RT.; Day, B.; Hanemann, N.; Hett, T.; Hanley, N.; Jones-Lee, M.; Loomes, G.;
Mourato, S.; Ozdemiroglu, E., et al. Economic Valuation with Stated Preference Techniques: A
Manual (In Association With the UK Department for Transport). Edward Elgar Publishers;
Cheltenham, UK: 2002.
Byford S, Raftery J. Economic notes: Perspectives in economic evaluation. BMJ. 1998; 316:1529.
[PubMed: 9582152]
Byford S, Torgerson DJ, Raftery J. Economic Note: Cost of illness studies. BMJ. 2000; 320:1335.
[PubMed: 10807635]
Cartwright J, Duncan WC, Critchley HO, Horne AW. Serum biomarkers of tubal ectopic pregnancy:
current candidates and future possibilities. Reproduction. 2009; 138(1):9–22. [PubMed: 19321656]
Cochrane, AL. Effectiveness and Efficiency: random reflections on health services. Royal Society of
Medicine Press; London, UK: 1999.
Critchley HO, Warner P, Lee AJ, Brechin S, Guise J, Graham B. Evaluation of abnormal uterine
bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal
status. Health Technol Assess. 2004; 8:1–139.
Drummond, MF.; Sculpher, MJ.; Torrance, GW.; O’Brien, B.; Stoddart, GL. Methods for the
Economic Evaluation of Health Care Programmes. 3rd edn. Oxford University Press; Oxford, UK:
2005.
Durston WE, Carl ML, Guerra W, Eaton A, Ackerson LM. Ultrasound availability in the evaluation of
ectopic pregnancy in the ED: comparison of quality and cost-effectiveness with different
approaches. Am J Emerg Med. 2000; 18:408–17. [PubMed: 10919529]
Farquhar CM. Ectopic pregnancy. Lancet. 2005; 366:583–91. [PubMed: 16099295]
Gracia CR, Barnhart KT. Diagnosing ectopic pregnancy: decision analysis comparing six strategies.
Obstet Gynaecol. 2001; 97:464–70.
Horne AW, van den Driesche S, King AE, Burgess S, Myers M, Ludlow H, Lourenco P, Ghazal P,
Williams AR, Critchley HO, et al. Endometrial inhibin/activin beta-B subunit expression is related
to decidualization and is reduced in tubal ectopic pregnancy. J Clin Endocrinol Metab. 2008;
93:2375–82. [PubMed: 18381568]
Wedderburn et al. Page 7
Hum Reprod. Author manuscript; available in PMC 2010 November 23.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Horne AW, Duncan WC, King AE, Burgess S, Lourenco PC, Cornes P, Ghazal P, Williams AR, Udby
L, Critchley HO. Endometrial cysteine-rich secretory protein 3 is inhibited by human chorionic
gonadotropin, and is increased in the decidua of tubal ectopic pregnancy. Mol Hum Reprod. 2009
2009 [Epub ahead of print].
Johnston K, Buxton MJ, Jones DR, Fitzpatrick R. Assessing the costs of healthcare technologies in
clinical trials. Health Technol Assess. 1999; 3:1–76. [PubMed: 10350450]
Kirkwood, BR.; Sterne, JAC. Essential Medical Statistics. 2nd edn. Blackwell Science Ltd; Oxford,
UK: 2003.
McIntosh E, Luengo-Fernandez R. Economic evaluation. Part 1: Introduction to the concepts of
economic evaluation in health care. J Fam Plann Reprod Health Care. 2006; 32:107–12. [PubMed:
16824302]
McIntosh E, Luengo-Fernandez R. Economic evaluation. Part 2: frameworks for combining costs and
benefits in health care. J Fam Plann Reprod Health Care. 2006; 32:176–80. [PubMed: 16857073]
Munro KI, Horne AW, Duncan WC, Critchley HOD. Features associated with time to diagnosis and
management of ectopic pregnancy. Scot Med J. 2008; 53:49.
National Institute of Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal.
NICE; London. UK: 2004.
Palmer S, Byford S, Raftery J. Economics Notes: Types of economic evaluation. BMJ. 1999;
318:1349. [PubMed: 10323827]
Robson SJ, O’Shea RT. Undiagnosed ectopic pregnancy: a retrospective analysis of 31 ‘missed’
ectopic pregnancies at a teaching hospital. Aust N Z J Obstet Gynaecol. 1996; 36:182–5.
[PubMed: 8798311]
RCOG. The management of tubal pregnancy. 2004Green-top No 21 Guideline. http://
www.rcog.org.uk/womens-health/clinical-guidance/management-tubal-pregnancy-21-may-2004
Ryan M, Donaldson C. Assessing the costs of assisted reproductive techniques. BJOG. 1996; 103:198–
201.
Saving Mothers’ Lives. Confidential Enquiry into Maternal Deaths 2003-5. 2008.
Seror V, Gelfucci F, Gerbaud L, Pouly JL, Fernandez H, Job-Spira N, Bouyer J, Coste J. Care
pathways for ectopic pregnancy: a population-based cost-effectiveness analysis. Fertil Steril. 2007;
87:737–48. [PubMed: 17222832]
Walker JJ. Ectopic pregnancy. Clin Obstet Gynecol. 2007; 50:89–99. [PubMed: 17304026]
Wedderburn et al. Page 8
Hum Reprod. Author manuscript; available in PMC 2010 November 23.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1.
Diagnostic care pathway for 175 patients.
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Figure 2.
Cumulative number of patients diagnosed ‘ectopic’ or ‘discharged’, and number continuing
as ‘non-diagnostic’ across successive hospital visits.
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